Elite in Diabetic Nephropathy

Hermann G. Haller

Carl Neuberg Str. 1, 
Hannover, NI, DE 
Elite in Diabetic Nephropathy
Carl Neuberg Str. 1, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Hermann Haller practices in Hannover, Germany. Haller is rated as an Elite expert by MediFind in the treatment of Diabetic Nephropathy. Their top areas of expertise are Hypertension, Diabetic Nephropathy, D-Minus Hemolytic Uremic Syndrome, Kidney Transplant, and Lung Transplant.

Their clinical research consists of co-authoring 419 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 28 articles in the study of Diabetic Nephropathy.

Locations

Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
View 1 Less Clinical Trial

419 Total Publications

Heparanase 2 Modulates Vascular Permeability via Heparan Sulfate-Dependent Growth Factor Signaling.
Heparanase 2 Modulates Vascular Permeability via Heparan Sulfate-Dependent Growth Factor Signaling.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: August 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Haller's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 18 Advanced Conditions
View All 60 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile